BioMarin Q4 2025 Revenue Beats Estimates but 2026 Guidance Concerns Investors
BioMarin's Q4 2025 revenue beat analyst forecasts, but weak full-year 2026 EPS guidance led to a stock decline, contrasting with sector stability.
Get instant access to more than 2 million reports, dashboards, and datasets on the IndexBox Platform.
View PricingThe Russian penicillins or streptomycins medicaments market reached $X in 2025, approximately reflecting the previous year. In general, consumption, however, saw a pronounced curtailment. Over the period under review, the market attained the peak level at $X in 2012; however, from 2013 to 2025, consumption failed to regain momentum.
In value terms, penicillins or streptomycins medicaments production stood at $X in 2025 estimated in export price. Over the period under review, production, however, continues to indicate a perceptible downturn. Penicillins or streptomycins medicaments production peaked at $X in 2012; however, from 2013 to 2025, production failed to regain momentum.
In 2025, the amount of medicaments of penicillins, streptomycins or derivatives thereof exported from Russia skyrocketed to X tons, with an increase of X% compared with the previous year. Overall, exports posted prominent growth. The growth pace was the most rapid in 2013 when exports increased by X%. As a result, the exports reached the peak of X tons. From 2014 to 2025, the growth of the exports failed to regain momentum.
In value terms, penicillins or streptomycins medicaments exports stood at $X in 2025. Over the period under review, total exports indicated a noticeable expansion from 2012 to 2025: its value increased at an average annual rate of X% over the last twelve-year period. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2025 figures, exports decreased by X% against 2021 indices. The most prominent rate of growth was recorded in 2017 with an increase of X% against the previous year. The exports peaked at $X in 2021; however, from 2022 to 2025, the exports remained at a lower figure.
Kyrgyzstan (X tons) was the main destination for penicillins or streptomycins medicaments exports from Russia, with a X% share of total exports. Moreover, penicillins or streptomycins medicaments exports to Kyrgyzstan exceeded the volume sent to the second major destination, Uzbekistan (X tons), threefold. The third position in this ranking was held by Armenia (X tons), with a X% share.
From 2012 to 2025, the average annual rate of growth in terms of volume to Kyrgyzstan totaled X%. Exports to the other major destinations recorded the following average annual rates of exports growth: Uzbekistan (X% per year) and Armenia (X% per year).
In value terms, Kyrgyzstan ($X) remains the key foreign market for medicaments of penicillins, streptomycins or derivatives thereof exports from Russia, comprising X% of total exports. The second position in the ranking was taken by Uzbekistan ($X), with a X% share of total exports. It was followed by Armenia, with a X% share.
From 2012 to 2025, the average annual rate of growth in terms of value to Kyrgyzstan stood at X%. Exports to the other major destinations recorded the following average annual rates of exports growth: Uzbekistan (X% per year) and Armenia (X% per year).
The average penicillins or streptomycins medicaments export price stood at $X per ton in 2025, with a decrease of X% against the previous year. Overall, the export price recorded a noticeable decline. The most prominent rate of growth was recorded in 2014 when the average export price increased by X% against the previous year. The export price peaked at $X per ton in 2021; however, from 2022 to 2025, the export prices stood at a somewhat lower figure.
Prices varied noticeably by country of destination: amid the top suppliers, the country with the highest price was Uzbekistan ($X per ton), while the average price for exports to Azerbaijan ($X per ton) was amongst the lowest.
From 2012 to 2025, the most notable rate of growth in terms of prices was recorded for supplies to Uzbekistan (X%), while the prices for the other major destinations experienced more modest paces of growth.
Penicillins or streptomycins medicaments imports into Russia shrank to X tons in 2025, declining by X% compared with the year before. The total import volume increased at an average annual rate of X% over the period from 2012 to 2025; however, the trend pattern indicated some noticeable fluctuations being recorded throughout the analyzed period. The pace of growth appeared the most rapid in 2023 when imports increased by X%. As a result, imports attained the peak of X tons, and then contracted in the following year.
In value terms, penicillins or streptomycins medicaments imports dropped to $X in 2025. Overall, imports showed a mild descent. The pace of growth was the most pronounced in 2019 when imports increased by X%. As a result, imports reached the peak of $X. From 2020 to 2025, the growth of imports remained at a somewhat lower figure.
The UK (X tons), Poland (X tons) and India (X tons) were the main suppliers of penicillins or streptomycins medicaments imports to Russia, with a combined X% share of total imports. Italy, Greece, the Netherlands and Germany lagged somewhat behind, together accounting for a further X%.
From 2012 to 2025, the biggest increases were recorded for Greece (with a CAGR of X%), while purchases for the other leaders experienced more modest paces of growth.
In value terms, the UK ($X) constituted the largest supplier of medicaments of penicillins, streptomycins or derivatives thereof to Russia, comprising X% of total imports. The second position in the ranking was taken by India ($X), with a X% share of total imports. It was followed by Poland, with an X% share.
From 2012 to 2025, the average annual rate of growth in terms of value from the UK amounted to X%. The remaining supplying countries recorded the following average annual rates of imports growth: India (X% per year) and Poland (X% per year).
The average penicillins or streptomycins medicaments import price stood at $X per ton in 2025, remaining constant against the previous year. In general, the import price, however, saw a perceptible setback. The pace of growth was the most pronounced in 2019 when the average import price increased by X%. As a result, import price attained the peak level of $X per ton. From 2020 to 2025, the average import prices failed to regain momentum.
There were significant differences in the average prices amongst the major supplying countries. In 2025, amid the top importers, the country with the highest price was the UK ($X per ton), while the price for Greece ($X per ton) was amongst the lowest.
From 2012 to 2025, the most notable rate of growth in terms of prices was attained by India (X%), while the prices for the other major suppliers experienced mixed trend patterns.
This report provides a comprehensive view of the penicillins or streptomycins medicaments industry in Russia, tracking demand, supply, and trade flows across the national value chain. It explains how demand across key channels and end-use segments shapes consumption patterns, while also mapping the role of input availability, production efficiency, and regulatory standards on supply.
Beyond headline metrics, the study benchmarks prices, margins, and trade routes so you can see where value is created and how it moves between domestic suppliers and international partners. The analysis is designed to support strategic planning, market entry, portfolio prioritization, and risk management in the penicillins or streptomycins medicaments landscape in Russia.
The report combines market sizing with trade intelligence and price analytics for Russia. It covers both historical performance and the forward outlook to 2035, allowing you to compare cycles, structural shifts, and policy impacts.
This report provides a consistent view of market size, trade balance, prices, and per-capita indicators for Russia. The profile highlights demand structure and trade position, enabling benchmarking against regional and global peers.
The analysis is built on a multi-source framework that combines official statistics, trade records, company disclosures, and expert validation. Data are standardized, reconciled, and cross-checked to ensure consistency across time series.
All data are normalized to a common product definition and mapped to a consistent set of codes. This ensures that comparisons across time are aligned and actionable.
The forecast horizon extends to 2035 and is based on a structured model that links penicillins or streptomycins medicaments demand and supply to macroeconomic indicators, trade patterns, and sector-specific drivers. The model captures both cyclical and structural factors and reflects known policy and technology shifts in Russia.
Each projection is built from national historical patterns and the broader regional context, allowing the report to show where growth is concentrated and where risks are elevated.
Prices are analyzed in detail, including export and import unit values, regional spreads, and changes in trade costs. The report highlights how seasonality, freight rates, exchange rates, and supply disruptions influence pricing and margins.
Key producers, exporters, and distributors are profiled with a focus on their operational scale, geographic footprint, product mix, and market positioning. This helps identify competitive pressure points, partnership opportunities, and routes to differentiation.
This report is designed for manufacturers, distributors, importers, wholesalers, investors, and advisors who need a clear, data-driven picture of penicillins or streptomycins medicaments dynamics in Russia.
The market size aggregates consumption and trade data, presented in both value and volume terms.
The projections combine historical trends with macroeconomic indicators, trade dynamics, and sector-specific drivers.
Yes, it includes export and import unit values, regional spreads, and a pricing outlook to 2035.
The report benchmarks market size, trade balance, prices, and per-capita indicators for Russia.
Yes, it highlights demand hotspots, trade routes, pricing trends, and competitive context.
Making Data-Driven Decisions to Grow Your Business
A Quick Overview of Market Performance
Understanding the Current State of The Market and its Prospects
Finding New Products to Diversify Your Business
Choosing the Best Countries to Establish Your Sustainable Supply Chain
Choosing the Best Countries to Boost Your Export
The Latest Trends and Insights into The Industry
The Largest Import Supplying Countries
The Largest Destinations for Exports
The Largest Producers on The Market and Their Profiles
BioMarin's Q4 2025 revenue beat analyst forecasts, but weak full-year 2026 EPS guidance led to a stock decline, contrasting with sector stability.
Gilead Sciences stock has significantly outperformed the market since March 2021, but an analysis reveals underlying business concerns including slow sales growth and declining financial metrics, suggesting potential better investment opportunities.
Gossamer Bio's Q4 2025 financial report shows a $47.2M loss but revenue of $13.8M beat analyst predictions, with full-year 2025 revenue at $48.5M.
Kyntra Bio executives detail 2025 progress on key cancer drug candidates and future strategy in a recent conference call, outlining clinical developments and forward-looking business statements.
Assertio Holdings reports on its 2025 financial performance, completes Rolvedon integration, and outlines a new strategy focusing on its core asset while moving away from its previous acquisition-based growth model.
A recent analysis reveals divergent prospects for S&P 500 companies, with healthcare firms IQVIA and Bristol-Myers Squibb facing specific headwinds, while consumer giant Coca-Cola is highlighted for attention.
Verified reviewers highlight faster qualification, clearer collaboration, and stronger bid readiness.
High Performer
Regional Grid
High Performer Small-Business
Grid Report
Leader Small-Business
Grid Report
High Performer Mid-Market
Grid Report
Leader
Grid Report
Users Love Us
Milestone badge
Cristian Spataru
Commercial Manager · XTRATECRO
Great for Market Insights and Analysis
“IndexBox is a solid source for trade and industrial market data — what I like best about it is how it aggregates official statistics.”
Review collected and hosted on G2.com.
Juan Pablo Cabrera
Gerente de Innovación · Cartocor
Extremely gratifying
“Access very specific and broad information of any type of market.”
Review collected and hosted on G2.com.
Dilan Salam
GMP; ISO Compliance Supervisor · PiONEER Co. for Pharmaceutical Industries
Powerful data at a fair price
“I have got a lot of benefit from IndexBox, too many data available, and easy to use software at a very good price.”
Review collected and hosted on G2.com.
Counselor Hasan AlKhoori
Founder and CEO · Independent
All the data required
“All the data required for building your full analytics infrastructure.”
Review collected and hosted on G2.com.
Ashenafi Behailu
General Manager · Ashenafi Behailu General Contractor
Detailed, well-organized data
“The data organization and level of detail which it is presented in is very helpful.”
Review collected and hosted on G2.com.
Iman Aref
Senior Export Manager · Padideh Shimi Gharn
Up to date and precise info
“Up to date and precise info, for fulfilling the validity and reliability of the given research.”
Review collected and hosted on G2.com.
Companies list is being prepared. Please check back soon.
Charts mirror the report figures on the platform. Values are synthetic for demo use.
| Top consuming countries | Share, % |
|---|
| Segment | Growth, % |
|---|
| Segment | Kg per capita |
|---|
| Top producing countries | Share, % |
|---|
| Top export price | USD per ton |
|---|
| Top import price | USD per ton |
|---|
| Top importing countries | Share, % |
|---|
| Top import price | USD per ton |
|---|
| Top exporting countries | Share, % |
|---|
| Top export price | USD per ton |
|---|
| Segment | Growth, % |
|---|
| Segment | Growth, % |
|---|
| Product | Rationale |
|---|
Real macro, logistics, and energy indicators are pulled from the IndexBox platform and rendered on demand.
This report provides an in-depth analysis of the global market for penicillins or streptomycins medicaments.
This report provides an in-depth analysis of the market for penicillins or streptomycins medicaments in Asia.
This report provides an in-depth analysis of the market for penicillins or streptomycins medicaments in China.
This report provides an in-depth analysis of the market for penicillins or streptomycins medicaments in the U.S..
This report provides an in-depth analysis of the market for penicillins or streptomycins medicaments in the EU.
This report provides an in-depth analysis of the global antibiotic market.
This report provides an in-depth analysis of the global vitamin market.
This report provides an in-depth analysis of the global antisera market.
This report provides an in-depth analysis of the vitamin market in Iraq.
Instant access. No credit card needed.
Instant access. No credit card needed.